Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
intravenous immunoglobulin
- Development stage
- Unknown
- Lead developer
- Circulate Health
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This refers to a therapeutic protocol combining Therapeutic Plasma Exchange (TPE) with Intravenous Immunoglobulin (IVIG) aimed at reducing biological age and reversing age-related biomarkers. Developed by Circulate, Inc. in collaboration with Dr. Dobri Kiprov (Global Apheresis) and the Buck Institute for Research on Aging, the intervention involves removing a patient's plasma and replacing it with fluids and IVIG. IVIG is a biologic therapy composed of pooled human antibodies. The mechanism involves modulating the immune system, reducing chronic inflammation (inflammaging), and restoring youthful immune cell composition. A Phase 3 trial demonstrated a reduction in biological age (approximately 2.6 years) as measured by epigenetic clocks and multi-omics biomarkers.
- Other names
- IVIGintravenous immunoglobulin-Dobri Kiprov-AgingTPE + IVIGtherapeutic plasma exchange with intravenous immunoglobulin
02
Targets
FCER2 (Low affinity immunoglobulin epsilon fc receptor)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)FCGRT (Neonatal crystallizable fragment receptor)Neuraminidase
Beyond the preview
Go deeper on intravenous immunoglobulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on intravenous immunoglobulin.